InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Friday, 05/31/2019 2:40:41 PM

Friday, May 31, 2019 2:40:41 PM

Post# of 43366
News: $HGEN Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclon...

In case you are interested https://marketwirenews.com/news-releases/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-xae-axicabtagene-ciloleucel-with-lenzilumab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-8277292.html
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.